

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appln. No.

: 10/601,968

Confirmation No.: 8810

Applicant

: Fensome et al.

Filed

: June 23, 2003

TC/A.U.

: 1614

Examiner

: B. Kwon

Customer No.

: 38199

Title

: CYCLOTHIOCARBAMATE DERIVATIVES AS

PROGESTERONE RECEPTOR MODULATORS AND

METHODS OF TREATING SKIN DISORDERS

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SIXTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Applicant submits to the Examiner the attached Form PTO/SB/08B document listing and this paper pursuant to 37 CFR § 1.56 and § 1.97-1.98. Form PTO/SB/08B is attached and copies of the documents are enclosed herewith. This Information Disclosure Statement is submitted less than three months from the filing date of this application and before the receipt of a first Office Action on the merits. Therefore, no fees are believed due.

The Director is hereby authorized to charge any deficiency in any fees due with the filing of this paper or during the pendency of this application, or credit any overpayment in any fees to our Deposit Account Number 08-3040.

06/02/2006 TBESHAH1 00000003 10601968 02 FC:1806

180.60 Op

Express Mail No. EQ543967191US

REMARKS

Listed below is a document cited in an Office Action dated February 17, 2006 issued in the counterpart Taiwanese Patent Application No. 92116986. A copy of an English translation of the Office Action is enclosed as document AT, together with a copy of the following document.

و و مسلم

(AS) VAN VLOTEN et al., "The Effect of 2 Combined Oral Contraceptives Containing Either Drospirenone or Cyproterone Acetate on Acne and Seborrhea", Cutis 69: 2 (April, 2002)

The Examiner is respectfully requested to consider the enclosed documents identified in this paper and in the attached Form PTO/SB/08B during the course of examination of this application.

Respectfully submitted,

HOWSON AND HOWSON

y _____

Registration No. 33,980

Suite 210

501 Office Center Drive Fort Washington, PA 19034

Telephone: (215) 540-9200 Telefacsimile: (215) 540-5818



Approved for use through 06/30/2006.
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

First Name

Application Number 10/601,968

Filing Date June 23, 2003

First Named Inventor Fensome et al.

Art Unit 1614

Examiner Name B. Kwon

Attorney Docket Number AHPWA23AUSA

(Use as many sheets as necessary)
Sheet 1 of 1

NON PATENT LITERATURE DOCUMENTS Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of Examiner Cite the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue Initials* No.1 T² number(s), publisher, city and/or country where published AS VAN VLOTEN et al., "The Effect of 2 Combined Oral Contraceptives Containing Either Drospirenone or Cyproterone Acetate on Acne and Seborrhea", Cutis 69: 2 (April, 2002) AT English translation of an Office Action dated February 17, 2006 issued in counterpart Taiwanese Patent Application No. 92116986 ΑU English translation of an Office Action dated March 3, 2006 issued in counterpart Chinese Patent Application No. 03815194.4 AV English translation of an Office Action dated March 3, 2006 provided by our agent in counterpart Chilean Patent Application No. 1280/2003 AW FENSOME et al., "Synthesis and Structure-Activity Relationship of Novel 6-Aryl-1,4-Dihydrobenzo[d][1,3]oxazine-2-thiones as Progesterone Receptor Modulators Leading to the Potent and Selective Nonsteroidal Progesterone Receptor Agonists Tanaproget", J. Med. Chem, 48:5092-5095 (2005) AX ZHANG et al., "Novel 6-Aryl-1,4-Dihydrobenzo[d][1,3]oxazine-2-thiones as Potent, Selective, and Orally Active Nonsteroidal Progesterone Receptor Agonists", Bioorg. & Med. Chem. Lett., 13:1313-1316 (2003).

Examiner	Date
Signature	Considered

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.